SMS Pharmaceuticals Ltd — earnings calls

SMS Pharmaceuticals reported 13% revenue growth to INR887 crores and EBITDA margin expansion to 20% for FY26, with PAT rising 47% to INR102 crores including a contribution from associate VKT Pharma. Management attributed the improvement to backward integration in ibuprofen, favorable product mix and operating leverage, while noting the anti-diabetic segment was deprioritized in favor of ARV and anti-inflammatory APIs. For FY27, management guided to 15% revenue growth and further margin improvement from the FY26 level of 20%, citing geopolitical uncertainty affecting logistics and raw material costs.